Fig. 1

Node diagram of prostate cancer screening, diagnosis, and treatment pathway indicating the percentage of screen eligible patients who move through each node. a PSA screening practice data from a large, multispecialty group from April 1, 2013 to March 31, 2014 was used to model screening prevalence for age groups 50-54, 55-69, and 70+ years. b D’Amico low risk: PSA less than or equal to 10, a Gleason score less than or equal to 6, or are in clinical stage T1-2a. c. D’Amico intermediate risk: PSA between 10 and 20, a Gleason score of 7, or are in clinical stage T2b. d. D’Amico high risk: PSA more than 20, a Gleason score equal or larger than 8, or are in clinical stage T2c-3a. Note: Prostate Specific Antigen (PSA), Prostate Cancer (PC), Hormone Therapy (HT)